J Korean Med Sci.  2022 Jan;37(2):e15. 10.3346/jkms.2022.37.e15.

Rhinovirus Incidence Rates Indicate We Are Tired of Non-pharmacological Interventions Against Coronavirus Disease 2019

• Kim MC
• Park JH
• Choi SH
• Chung JW

• KMID: 2524287
• DOI: http://doi.org/10.3346/jkms.2022.37.e15

Abstract

Background
During the coronavirus disease 2019 (COVID-19) pandemic, the incidence of rhinovirus (RV) is inversely related to the intensity of non-pharmacological interventions (NPIs), such as universal mask wearing and physical distancing.
Methods
Using RV surveillance data, changes in the effect of NPIs were investigated in South Korea during the pandemic. The time to the first visible effect of NPIs after the onset of NPIs (T1), time to the maximum effect (T2), and duration of the maximum effect (T3) were measured for each surge. For each week, the RVdiff [(RV incidence during the pandemic) − (RV incidence within 5 years before the pandemic)] was calculated, and number of weeks for RVdiff to be below zero after NPIs (time to RVdiff ≤ 0) and number of weeks RVdiff remains below zero after NPIs (duration of RVdiff ≤ 0) were measured for each surge.
Results
During the study period, four surges of COVID-19 were reported. As the pandemic progressed, T1 and T2 increased, but T3 decreased. Additionally, the “time to RVdiff of ≤ 0” increased and “duration of RVdiff of ≤ 0” decreased. These changes became more pronounced during the third surge (mid-November 2020), before the introduction of the COVID-19 vaccine, and from the emergence of the delta variant.
Conclusion
The effect of NPIs appears slower, the duration of the effect becomes shorter, and the intensity also decreases less than a year after the onset of the pandemic owing to people’s exhaustion in implementing NPIs. These findings suggest that the COVID-19 response strategy must be completely overhauled

Keyword

Rhinovirus; COVID-19; Non-pharmacological Intervention; Time of Effects

Figure

• 

  Fig. 1 Weekly numbers of patients with COVID-19 and of persons who received COVID-19 vaccination between the first week of 2020 and the 34th week of 2021 in South Korea. The dark blue line indicates the weekly number of COVID-19 patients. The orange line indicates the weekly proportion of people who received more than one dose of COVID-19 vaccination. The red line indicates the weekly proportion of those who have completed the vaccination schedule. Black circles with white numbers indicate the four COVID-19 surges. Boxes indicate the comments related to the appearance of the delta variant in South Korea. Each week is designated by a four-digit number (YYWW) (e.g., 2012 and 2112 indicate the 12th week of 2020 and 2021, respectively).COVID-19 = coronavirus disease 2019, SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2.

• 

  Fig. 2 (A) Weekly number of patients with COVID-19, weekly positivity rate of RV during the pandemic, and the level of intensity of non-pharmacological interventions against COVID-19 between the first week of 2020 and the 34th week of 2021 in South Korea. (B) Weekly value of RVdiff. The dark blue line indicates the number of COVID-19 patients. The red line indicates the weekly positivity rate of RV during the pandemic. The dotted line indicates the weekly mean positivity rate of RV before the pandemic (2015–2019). RVdiff indicates the difference in the weekly RV positivity rate between the pandemic period and the pre-pandemic period (in Fig. 2A, an example of RVdiff is introduced). The three boxes indicate the time to the first visible effect (T1), time to the maximum effect (T2), and duration of the maximum effect (T3) of non-pharmaceutical interventions implemented in each COVID-19 surge. Each week is designated by a four-digit number (YYWW) (e.g., 2012 and 2112 indicate the 12th week of 2020 and 2021, respectively).COVID-19 = coronavirus disease 2019, RV = rhinovirus.

• 

  Fig. 3 Weekly number of patients with COVID-19, weekly positivity rate of human BOV during the pandemic, and the level of intensity of non-pharmacological interventions against COVID-19 between the first week of 2020 and the 34th week of 2021 in South Korea. The dark blue line indicates the number of COVID-19 patients. The orange line indicates the weekly positivity rate of BOV during the pandemic. The dotted line indicates the weekly mean proportion of BOV before the pandemic (2015–2019). The horizontal line indicates the maximum value of the weekly mean proportion of BOV before the pandemic. Each week is designated by a four-digit number (YYWW) (e.g., 2012 and 2112 indicate the 12th week of 2020 and 2021, respectively).COVID-19 = coronavirus disease 2019, BOV = bocavirus.

• 

  Fig. 4 Weekly number of patients with COVID-19, weekly positivity rate of ADV during the pandemic, and the level of intensity of non-pharmacological interventions against COVID-19 between the first week of 2020 and the 34th week of 2021 in South Korea. The dark blue line indicates the number of COVID-19 patients. The light blue line indicates the weekly proportion of ADV during the pandemic. The dotted line indicates the weekly mean proportion of ADV before the pandemic (2015–2019). The horizontal line indicates the maximum value of the weekly mean proportion of ADV before the pandemic. Each week is designated by a four-digit number (YYWW) (e.g., 2012 and 2112 indicate the 12th week of 2020 and 2021, respectively).COVID-19 = coronavirus disease 2019, ADV = adenovirus.

Reference

1. Yoo JH. The fight against the 2019-nCoV outbreak: an arduous march has just begun. J Korean Med Sci. 2020; 35(4):e56. PMID: 31997618.

2. Kim MN. What type of face mask is appropriate for everyone-mask-wearing policy amidst COVID-19 pandemic? J Korean Med Sci. 2020; 35(20):e186. PMID: 32449327.

3. Jang WM, Jang DH, Lee JY. Social distancing and transmission-reducing practices during the 2019 coronavirus disease and 2015 middle east respiratory syndrome coronavirus outbreaks in Korea. J Korean Med Sci. 2020; 35(23):e220. PMID: 32537955.

4. Bae S, Lee YW, Lim SY, Lee JH, Lim JS, Lee S, et al. Adverse reactions following the first dose of ChAdOx1 nCoV-19 vaccine and BNT162b2 vaccine for healthcare workers in South Korea. J Korean Med Sci. 2021; 36(17):e115. PMID: 33942579.

5. Korea Disease Control and Prevention Agency. Coronavirus disease 2019 (COVID-19). Updated 2021. Accessed September 2, 2021. http://ncov.mohw.go.kr .

6. Rodgers L, Sheppard M, Smith A, Dietz S, Jayanthi P, Yuan Y, et al. Changes in seasonal respiratory illnesses in the United States during the coronavirus disease 2019 (COVID-19) pandemic. Clin Infect Dis. 2021; 73(Suppl 1):S110–S117. PMID: 33912902.

7. Redlberger-Fritz M, Kundi M, Aberle SW, Puchhammer-Stöckl E. Significant impact of nationwide SARS-CoV-2 lockdown measures on the circulation of other respiratory virus infections in Austria. J Clin Virol. 2021; 137:104795. PMID: 33761423.

8. Park KY, Seo S, Han J, Park JY. Respiratory virus surveillance in Canada during the COVID-19 pandemic: an epidemiological analysis of the effectiveness of pandemic-related public health measures in reducing seasonal respiratory virus test positivity. PLoS One. 2021; 16(6):e0253451. PMID: 34143839.

9. Chen APL, Chu IYH, Yeh ML, Chen YY, Lee CL, Lin HH, et al. Differentiating impacts of non-pharmaceutical interventions on non-coronavirus disease-2019 respiratory viral infections: Hospital-based retrospective observational study in Taiwan. Influenza Other Respir Viruses. 2021; 15(4):478–487. PMID: 33825310.

10. Park S, Michelow IC, Choe JY. Shifting patterns of respiratory virus activity following social distancing measures for coronavirus disease 2019 in South Korea. J Infect Dis. 2021; 224(11):1900–1906. PMID: 34009376.

11. Haapanen M, Renko M, Artama M, Kuitunen I. The impact of the lockdown and the re-opening of schools and day cares on the epidemiology of SARS-CoV-2 and other respiratory infections in children – a nationwide register study in Finland. EClinicalMedicine. 2021; 34:100807. PMID: 33817612.

12. Sullivan GS, Carlson S, Cheng AC, Chilver MB, Dwyer DE, Irwin M, et al. Where has all the influenza gone? The impact of COVID-19 on the circulation of influenza and other respiratory viruses, Australia, March to September 2020. Euro Surveill. 2020; 25(47):2001847.

13. Nawrocki J, Olin K, Holdrege MC, Hartsell J, Meyers L, Cox C, et al. The effects of social distancing policies on non-SARS-CoV-2 respiratory pathogens. Open Forum Infect Dis. 2021; 8(7):ofab133. PMID: 34322558.

14. Kim MC, Kweon OJ, Lim YK, Choi SH, Chung JW, Lee MK. Impact of social distancing on the spread of common respiratory viruses during the coronavirus disease outbreak. PLoS One. 2021; 16(6):e0252963. PMID: 34125839.

15. Kitanovski S, Horemheb-Rubio G, Adams O, Gärtner B, Lengauer T, Hoffmann D, et al. Rhinovirus prevalence as indicator for efficacy of measures against SARS-CoV-2. BMC Public Health. 2021; 21(1):1178. PMID: 34154549.

16. Poole S, Brendish NJ, Tanner AR, Clark TW. Physical distancing in schools for SARS-CoV-2 and the resurgence of rhinovirus. Lancet Respir Med. 2020; 8(12):e92–e93. PMID: 33289636.

17. Our world in Data. Coronavirus (COVID-19) vaccinations. Updated 2021. Accessed September 2, 2021. https://ourworldindata.org/covid-vaccinations?country=KOR .

18. Luo CH, Morris PC, Sachithanandham J, Amadi A, Gastron D, Li M, et al. Infection with the SARS-CoV-2 delta variant is associated with higher infectious virus loads compared to the alpha variant in both unvaccinated and vaccinated individuals. medRxiv. DOI: 10.1101/2021.08.15.21262077. August 20, 2021.

19. Lessler J, Reich NG, Brookmeyer R, Perl TM, Nelson KE, Cummings DA. Incubation periods of acute respiratory viral infections: a systematic review. Lancet Infect Dis. 2009; 9(5):291–300. PMID: 19393959.